Veracyte (VCYT) investor relations material

Opening remarks and agenda

• Chair welcomed attendees, introduced board members, executive team, auditors, and legal counsel.

• Meeting was called to order and the agenda was outlined, including director elections, auditor ratification, executive compensation, and equity plan amendment.

Corporate governance

• Notice of meeting and voting rights were confirmed for stockholders of record as of April 15, 2026.

• Quorum was established with 91% of shares represented, allowing business to proceed.

• Inspector of Election and voting procedures were detailed, ensuring transparency and compliance.

Overview of voting outcomes

• All nine nominated directors were elected for a one-year term expiring at the 2027 annual meeting.

• Appointment of Ernst & Young LLP as independent auditor for 2026 was ratified.

• Executive compensation was approved on a non-binding advisory basis.

• Amendment to the 2023 Equity Incentive Plan, increasing authorized shares by 3.5 million, was approved.